Once a week, the development daily Novo nor Nordisk has a long-acting basic insulin comparable to Lantus

Roche releases new data from the two-year SMA study on risdiplam the treatment of infants, children and adults; Lilly Trulicity Efficacy Beats Somarudandands and Essenatide; Mercaton GARDASIL 9 Approved by the FDA for the Prevention of Certain HPV-related Head and Neck CancersWe focus on the latest developments in pharmaceutical research and development, to provide research and development personnel with timely and accurate information referencerecently, at the 80th Scientific Meeting of the American Diabetes Association, Novo Nordisk announced the results of a Phase II clinical trial of insulin icodec, a long-acting, long-acting insulin icodec, once a weekThe data showed that in adults with type 2 diabetes, insulin icodec had similar blood sugar control and similar safety when it came with insulin glargine products once a day, Roche's Genetek released positive data on two years of treatment for risdiplam in patients with type 2-2 or type 3 spinal muscular dystrophy (SMA) in part 1 of SUNFISHat the 25th annual meeting of the European Society of Hematology, Johnson and Johnson's Janssen Pharmaceuticals released data from Darzalex's phase III trial called ANDROMEDAThe results showed that Darzalex Faspro combination therapy reached the primary endpoint of hematologic complete remission rate (53% vs.18%, OR 5.1, 95% CI 3.2-8.2; P 0.0001)Novo Nordisk recently announced the top-line results of the last two Phase IIIa clinical trials in the Samaritide Weight Loss Efficacy III STEP projectThe results showed that a weekly subcutaneous injection of 2.4 mg of semaglutide resulted in a statistically significant reduction in weight compared to comfortAstraZeneca recently announced at the 25th annual meeting of the European Society of Hematology the detailed results of the trial of the first-line single-drug treatment of patients with chronic lymphocytic leukemia, the results showed that Calquance single-drug first-line treatment of primary CLL patients 4 years total remission rate of up to 97%, treatment of recurrence / difficult treatment of CLL patients 18 months survival rate as high as 88%, and show long-term good safetyLilly recently presented a new real-world study at the 80th Scientific Meeting of the American Diabetes Association showing that trulicity has significantly higher compliance and longer persistence in newly treated with GLP-1 receptor agonists in patients with type 2 diabetes compared to weekly injections of samarutide or ethaneOn the 15th, Beida Pharmaceuticals issued a notice that recently, the company received the "receiving notice" issued by the State Drug Administration, the company declared that the Bevalju singofa injection for advanced, metastatic or recurrent non-small cell lung cancer and metastatic colorectal cancer patients' treatment of the listing license application has been accepted by the State Drug Administration13, Mercado announced that the U.SFDA has approved GARDASIL 9 for the prevention of oral and other head and neck cancers caused by the human papillomavirus (HPV) type 16, 18, 31, 33, 45, 52 and 58.